Clinical and experimental treatment of type 1 diabetes.
Clinical and experimental treatment of type 1 diabetes.
复制标题
1 型糖尿病的临床和实验治疗。
DOI：
10.1093/cei/uxac077
复制
发表时间：
2022
影响因子：
4.6
通讯作者：
Buckner,JaneH
中科院分区：
文献类型：
--
作者：
Long,SAlice;Buckner,JaneH
1型糖尿病(T1D)是一种自身免疫性疾病，导致产生胰岛素的胰岛β细胞被破坏。疾病的进展是沿着从遗传风险、胰岛自身抗体的发展和自身反应性T细胞最终进展到临床疾病的轨迹进行的。与临床试验相联系的自然历史研究和机制研究为免疫系统在疾病发病机制中的作用提供了洞察力。在这里，我们回顾了我们目前对T1D潜在病因学的理解，重点是与从症状前T1D进展到临床诊断和既定疾病有关的免疫细胞类型。这一知识为以预防和治疗T1D为目的的免疫疗法的发展奠定了基础。
Type 1 diabetes (T1D) is an autoimmune disease resulting in the destruction of the insulin-producing pancreatic beta cells. Disease progression occurs along a trajectory from genetic risk, the development of islet autoantibodies, and autoreactive T cells ultimately progressing to clinical disease. Natural history studies and mechanistic studies linked to clinical trials have provided insight into the role of the immune system in disease pathogenesis. Here, we review our current understanding of the underlying etiology of T1D, focusing on the immune cell types that have been implicated in progression from pre-symptomatic T1D to clinical diagnosis and established disease. This knowledge has been foundational for the development of immunotherapies aimed at the prevention and treatment of T1D.